Spyre Therapeutics, Inc. SYRE Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s cash & equivalents?
- Spyre Therapeutics, Inc. (SYRE) reported cash & equivalents of $97.19M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s cash & equivalents changed year-over-year?
- Spyre Therapeutics, Inc.'s cash & equivalents increased by 100.4% year-over-year, from $48.49M to $97.19M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s cash & equivalents?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s cash & equivalents has grown at a -1.0% compound annual growth rate (CAGR), from $90.1M to $85.72M.
- What does cash & equivalents mean?
- The total amount of cash and highly liquid assets a company holds that can be accessed immediately.
- How do you interpret cash & equivalents?
- An increase suggests a stronger ability to fund operations or recent capital raises, while a decrease indicates cash burn for R&D and operating expenses.
- How does cash & equivalents compare across companies?
- Biotech peers typically maintain high cash balances relative to total assets to ensure multi-year operational runway.